OMNI BIO PHARMACEUTICAL, INC. - FORM 10-Q

Attached files

file	filename
EX-10.2 - EXHIBIT 10.2 - OMNI BIO PHARMACEUTICAL, INC.	omnibio10q123109x102_2310.htm
EX-31.2 - EXHIBIT 31.2 - OMNI BIO PHARMACEUTICAL, INC.	omnibio10q123109x312_2310.htm
EX-10.3 - EXHIBIT 10.3 - OMNI BIO PHARMACEUTICAL, INC.	omnibio10q123109x103_2310.htm
EX-31.1 - EXHIBIT 31.1 - OMNI BIO PHARMACEUTICAL, INC.	omnibio10q123109x311_2310.htm
EX-32.1 - EXHIBIT 32.1 - OMNI BIO PHARMACEUTICAL, INC.	omnibio10q123109x321_2310.htm
EX-32.2 - EXHIBIT 32.2 - OMNI BIO PHARMACEUTICAL, INC.	omnibio10q123109x322_2310.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended December 31, 2009

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to ________

Commission file number: 000-52530

Omni Bio Pharmaceutical, Inc.

(Exact Name of Registrant as Specified in its Charter)

Colorado	20-8097969
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

5350 South Roslyn, Suite 400, Greenwood Village, CO 80111

(Address of principal executive offices, including zip code)

(303) 867-3415

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes[ ] No[ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [ ] (Do not check if a smaller reporting company)	Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

The number of shares outstanding of the registrant’s common stock as of January 29, 2010 was 27,242,485.

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY

TABLE OF CONTENTS

PART I: FINANCIAL INFORMATION

		Page
Item 1.	Financial Statements.

	Consolidated Balance Sheets – December 31, 2009 (unaudited) and March 31, 2009	3

	Consolidated Statements of Operations – For the three months ended December 31, 2009 and 2008 (unaudited)	4

	Consolidated Statements of Operations – For the nine months ended December 31, 2009 and 2008, and February 28, 2006 (Inception) through December 31, 2009 (unaudited)	5

	Consolidated Statements of Stockholders’ Equity – As of and for the nine months ended December 31, 2009 (unaudited)	6

	Consolidated Statements of Cash Flows – For the nine months ended December 31, 2009 and 2008, and February 28, 2006 (Inception) through December 31, 2009 (unaudited)	8

	Notes to Consolidated Financial Statements (unaudited)	10

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	25

Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	31

Item 4T.	Controls and Procedures.	31

PART II: OTHER INFORMATION

Item 1.	Legal Proceedings.	32

Item 1A.	Risk Factors.	32

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	32

Item 3.	Defaults Upon Senior Securities.	33

Item 4.	Submission of Matters to a Vote of Security Holders.	33

Item 5.	Other Information.	33

Item 6.	Exhibits.	34

Signature		35

- 2 -

Part I. FINANCIAL INFORMATION

Item 1. Financial Statements.

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY

(A Development Stage Company)

CONSOLIDATED BALANCE SHEETS

ASSETS	December 31, 2009			March 31, 2009
	(Unaudited)
Current assets:
Cash and cash equivalents	$	790,292		$	1,805,395
Other current assets		16,939			21,772
Total current assets		807,231			1,827,167

Property and equipment, net		1,169			2,250
Intangible assets, net		68,412			72,300
Total long-term assets		69,581			74,550

TOTAL ASSETS	$	876,812		$	1,901,717

LIABILITIES & STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	112,306		$	282,935
Amounts due to UCD under sponsored research agreement		81,300			321,300
Accrued liabilities		61,977			56,817
Accrued compensation and related benefits and taxes		7,625			211,012
Amounts due to related parties		4,500			138,261
Note payable – related party		-			132,000
Total current liabilities		267,708			1,142,325

Note payable – related party, net of discount of $6,000 and $15,000, respectively		19,000			10,000

Total liabilities		286,708			1,152,325

Commitments and Contingencies

Stockholders’ equity:
Preferred stock, $0.10 par value; 5,000,000 shares authorized; -0- shares issued and outstanding		-			-
Common stock, $0.001 par value; 200,000,000 shares authorized; 27,242,485 and 23,164,567 shares issued and outstanding, respectively		27,242			23,164
Additional paid-in capital		11,985,520			8,186,704
Deficit accumulated during the development stage		(11,422,658	)		(7,460,476	)
Total stockholders’ equity		590,104			749,392

TOTAL LIABILITIES AND STOCKHOLDERS’EQUITY	$	876,812		$	1,901,717

The accompanying notes are an integral part of these consolidated financial statements.

- 3 -

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the Three Months Ended December 31,
	2009			2008

Operating expenses:
General and administrative (including share-based compensation of $598,142 and $122,372, respectively)	$	831,519		$	239,952
Research and development		-			81,300
Total operating expenses		831,519			321,252

Loss from operations		(831,519	)		(321,252	)

Non-operating expenses:
Interest income (expense), net		1,063			(1,321	)
Accretion expense on notes payable – related party		(3,000	)		(17,386	)
Charge for modification to warrant		(528,000	)		-
Total non-operating expenses		(529,937	)		(18,707	)

Net loss	$	(1,361,456	)	$	(339,959	)

Basic and diluted net loss per share	$	(0.05	)	$	(0.02	)

Weighted average shares outstanding – basic and diluted		27,073,918			18,210,295

The accompanying notes are an integral part of these consolidated financial statements.

- 4 -

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the Nine Months Ended December 31,						February 28, 2006 (Inception) through December 31, 2009
	2009			2008

Operating expenses:
General and administrative (including share-based compensation of $1,314,164, $428,184 and $2,779,978, respectively)	$	1,931,874		$	761,540		$	4,890,130
License fee – related party		1,495,000			-			1,495,000
Research and development		-			241,300			1,132,497
Charge for common stock issued pursuant to license agreements		-			20,833			763,240
Total operating expenses		3,426,874			1,023,673			8,280,867

Loss from operations		(3,426,874	)		(1,023,673	)		(8,280,867	)

Non-operating expenses:
Interest income (expense), net		1,692			(1,843	)		(59,393	)
Accretion expense on notes payable – related party		(9,000	)		(21,386	)		(50,125	)
Charges for warrants issued in merger – related parties		-			-			(1,948,237	)
Charge for warrants issued in private placements – related parties		-			-			(403,350	)
Charges for modifications to warrants		(528,000	)		-			(680,686	)
Total non-operating expenses		(535,308	)		(23,229	)		(3,141,791	)

Net loss	$	(3,962,182	)	$	(1,046,902	)	$	(11,422,658	)

Basic and diluted net loss per share	$	(0.15	)	$	(0.06	)

Weighted average shares outstanding – basic and diluted		26,562,854			18,209,234

The accompanying notes are an integral part of these consolidated financial statements.

- 5 -

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

	Preferred Stock				Common Stock				Additional Paid-in Capital			Deficit Accumulated During Development Stage			Total Stockholders’ Equity
	Shares		Amount		Shares		Amount

Balances at March 31, 2009		-	$	-		23,164,567	$	23,164	$	8,186,704		$	(7,460,476	)	$	749,392
Conversion of related party note payable into common stock (April 2009 at $0.22 per share)						600,000		600		131,400						132,000
Common stock purchase warrants exercised for cash by related parties (June 2009; 200,000 at $0.01 per share and 1,175,356 at $0.001 per share)						1,375,356		1,375		1,800						3,175
Common stock purchase warrants exercised cashless (May and June 2009 at weighted average exercise price of $1.10 per share)						126,097		126		(126	)					-
Share-based compensation related to issuance of common stock purchase warrants (April 2009 at estimated weighted-average fair value of $0.87 per share)										238,787						238,787
Common stock purchase warrants exercised for cash by related parties (July and August 2009 at $0.001 per share)						774,644		775		-						775
Common stock purchase warrants exercised cashless by related parties . (July through September 2009 at weighted average exercise price of $0.75 per share)						485,387		485		(485	)					-
Common stock purchase warrants exercised cashless (August and September 2009 at weighted average exercise price of $1.10 per share)						268,720		269		(269	)					-
Share-based compensation related to issuance of common stock purchase warrants (July and August 2009 at estimated weighted average fair value of $2.51 per share)										477,235						477,235
Common stock purchase warrant issued to related party for license fee (September 2009 at estimated fair value of $2.26 per share and exercise price of $3.00 per share										1,470,000						1,470,000

The accompanying notes are an integral part of these consolidated financial statements.

- 6 -

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (continued)

	Preferred Stock			Common Stock				Additional Paid-in Capital			Deficit Accumulated During Development Stage			Total Stockholders’ Equity
	Shares		Amount	Shares		Amount

Common stock purchase warrants exercised cashless (October through December 2009 at weighted average exercise price of $1.02 per share)					291,714		292		(292	)					-
Common stock sold in private placement offering, net of offering costs of $39,000 (December 2009 at $2.50 per unit)					156,000		156		350,844						351,000
Share-based compensation related to issuance of common stock purchase warrants and common stock (October and December 2009 at estimated weighted average fair value of $2.50 per share)									598,142						598,142
Modification to common stock purchase warrants at estimated fair value of $2.11 per share									528,000						528,000
Contributed rent									3,780						3,780
Net loss												(3,962,182	)		(3,962,182	)

Balances at December 31, 2009 (Unaudited)	-	$	-		27,242,485	$	27,242	$	11,985,520		$	(11,422,658	)	$	590,104

The accompanying notes are an integral part of these consolidated financial statements.

- 7 -

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Nine Months Ended December 31,						February 28, 2006 (Inception) Through December 31, 2009
	2009			2008
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(3,962,182	)	$	(1,046,902	)	$	(11,422,658	)
Adjustments used to reconcile net loss to net cash used in operating activities:
Charge for warrant issued for purchase of license – related party		1,470,000			-			1,470,000
Common stock issued pursuant to license agreements		-			20,833			763,240
Share-based compensation		1,314,164			428,184			2,779,978
Accretion expense – related parties		9,000			21,386			50,125
Charge for warrants issued in merger transaction - related parties		-			-			1,948,237
Charge for warrants issued in private placement transactions - related parties		-			-			403,350
Charges for modifications to warrants		528,000			-			680,686
Depreciation and amortization		4,969			3,895			15,296
Contributed rent		3,780			4,620			19,740
Other non-cash credit		-			(2,836	)
Loss on disposal of equipment		-			-			2,444
Changes in operating assets and liabilities:
Other current assets		4,833			73			(19,038	)
Accounts payable		(169,629	)		9,628			268,501
Amounts due to UCD under sponsored research agreement		(241,000	)		321,300			81,300
Accrued liabilities and accrued compensation and related benefits and taxes		(198,227	)		173,340			(242,222	)
Amounts due to related parties		(133,761	)		17,987			208,382
Net cash used in operating activities		(1,370,053	)		(48,492	)		(2,992,639	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from reverse merger transactions		-			-			11,750
Purchase of licenses		-			(35,401	)		(35,401	)
Purchase of property and equipment		-			-			(7,423	)
Net cash used in investing activities		-			(35,401	)		(31,074	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the sale of common stock		351,000			-			2,850,055
Proceeds from the issuance of notes payable to related parties		-			75,000			825,000
Proceeds from the sale of common stock warrants		-			-			125,000
Proceeds from the exercise of common stock warrants		3,950			-			13,950
Net cash provided by financing activities		354,950			75,000			3,814,005

Net increase (decrease) in cash and cash equivalents		(1,015,103	)		(8,893	)		790,292
Cash and cash equivalents at beginning of period		1,805,395			17,309			-
Cash and cash equivalents at end of period	$	790,292		$	8,416		$	790,292

The accompanying notes are an integral part of these consolidated financial statements.

- 8 -

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)

(Unaudited)

	For the Nine Months Ended December 31,				February 28, 2006 (Inception) Through December 31, 2009
	2009		2008
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Cash paid for:
Interest	$	1,750	$	-	$	1,750
Income taxes	$	-	$	-	$	-

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

Note payable – related party converted to common stock	$	132,000	$	-
Issuance of common stock purchase warrants to related party pursuant to private placement transaction	$	69,962	$	-
Issuance of common stock pursuant to cashless exercises of warrants	$	1,172	$	-
Discounts on notes payable - related parties	$	-	$	56,125

The accompanying notes are an integral part of these consolidated financial statements.

- 9 -

OMNI BIO PHARMACEUTICAL, INC. AND SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

NOTE 1 - ORGANIZATION AND GOING CONCERN

Organization

Omni Bio Pharmaceutical, Inc. is the successor company of Across America Financial Services, Inc. (“Across America”), which was incorporated under Colorado law on December 1, 2005 as a wholly-owned subsidiary of Across America Real Estate Corp. Across America intended to act as a mortgage broker for commercial real estate transactions. However, no revenues were generated from this business.

On March 31, 2009, Across America completed the acquisition of Apro Bio Pharmaceutical Corporation (“Apro Bio”) pursuant to the terms of the Agreement of Merger and Plan of Reorganization, as amended (the "Merger") among Across America, Apro Bio and Across America Acquisition Corp. (“AAAC”), a Colorado corporation and a wholly-owned subsidiary of Across America. Under the terms of the Merger, AAAC was merged into Apro Bio and Apro Bio became a wholly-owned subsidiary of Across America. On May 27, 2009, Across America changed its name to Omni Bio Pharmaceutical, Inc. (“Omni”). The Merger was accounted for as a reverse acquisition with Apro Bio being treated as the acquirer for accounting purposes. Accordingly, for all periods presented, the financial statements of Apro Bio have been adopted as the historical financial statements of Omni. See further discussion in Note 2.

On March 31, 2008, Apro Bio was formed from the merger of Apro Bio Pharmaceutical Corporation (“Apro Utah”) and Maxcure Pharmaceutical, Inc. (“Maxcure”), with Maxcure being the surviving legal corporation and Apro Bio the deemed acquirer for accounting purposes. See further discussion in Note 2.

Apro Utah was originally incorporated under the laws of the state of Utah on February 28, 2006 for the purpose of advancing the underlying licensed scientific art to attain the ability to sell treatments and/or countermeasures commercially to the Federal Government related to bacterial infections. Maxcure was formed as a Colorado corporation on December 26, 2006 for the purpose of entering into a license agreement with the University of Colorado Denver (“UCD”), formerly known as the University of Colorado Health Science Center (“UCHSC”) and to pursue a research agreement with UCD to further scientific study on using FDA-approved pharmaceuticals in novel methods for treatment of bacterial infection.

Nature of Operations

Except as the context otherwise requires, the terms "Company," "we," "our" or "us" means Omni and its wholly-owned subsidiary, Omni Bio Operating, Inc. (“Omni Bio”).

From inception, we have been engaged in the sponsoring of research and development programs conducted by UCD and one other academic/research institution. Pursuant to two existing license agreements with the Regents of the University of Colorado (“RUC”), we have entered into one Sponsored Research Agreement (“SRA”) related to a pending patent for the treatment of bacterial infection utilizing Alpha 1-Antitrypsin (“AAT”) dated May 15, 2006, and are obligated to enter into additional SRAs under our license agreement dated March 31, 2008 for methods of use of an issued patent related to the treatment of HIV (human immunodeficiency virus). On November 12, 2008, we executed a third license agreement with RUC, which involves patent applications for methods of use of AAT for potential use in organ/graft transplantation rejection. We are also obligated to enter into an additional SRA under this license agreement. To date, we have not generated any revenues from our operations.

- 10 -

OMNI BIO PHARMACEUTICAL, INC. AND SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

Basis of Presentation

The accompanying unaudited consolidated financial statements are comprised of Omni and its wholly-owned subsidiary, Omni Bio, and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the unaudited consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements, and reflect all adjustments, consisting only of normal, recurring adjustments, necessary for a fair presentation in accordance with US GAAP. The results of operations for interim periods presented are not necessarily indicative of the operating results for the full year. These unaudited consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2009 (the “2009 10-K”). The balances as of March 31, 2009 are derived from our audited consolidated balance sheet.

Going Concern

The accompanying financial statements have been prepared in conformity with US GAAP, which contemplate our continuation as a going concern, whereby the realization of assets and liquidation of liabilities are in the ordinary course of business. We are currently in the development stage as we have not realized any revenue since inception. Activities have included: raising capital; reorganizations and mergers; and obtaining various rights, license agreements and a research and development agreement. We have incurred net losses since inception, and as of December 31, 2009, had a deficit accumulated from inception of $11.0 million, which included total non-cash charges from inception of approximately $7.7 million. These conditions raise substantial doubt as to our ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might be different should we be unable to continue as a going concern.

In December 2009, we enhanced our liquidity with the first closing of a private placement equity offering (the “PPO”), which generated net cash of $351,000 (after offering costs of $39,000). In January 2010, we completed two additional closings of the PPO and generated net cash of $1,436,000 (after offering costs of $160,000). See further discussion in Note 3. We believe that the capital raised in the PPO provides us cash to fund our current operations and research and development for the near term. Depending on the extent that we increase research and development through potential new licenses or pursue clinical trials in addition to our current budgeted one, we will likely need to raise additional capital through additional equity financings or through other means that we deem necessary. There is no assurance that we will be successful in raising additional capital on acceptable terms or at all. Further, even if we raise additional capital, there is no assurance that we will achieve profitability or positive cash flow in the near term or at all.

Share-based Compensation

We account for share-based compensation under FASB ASC Topic 718 Compensation – Stock Compensation (“Topic 718”). Topic 718 requires the recognition of equity-based payments to employees in the financial statements and is measured based on the estimated fair value of the award on the grant date. Topic 718 also requires the stock option or stock purchase warrant compensation expense to be recognized over the period during which an employee is required to provide service in exchange for the award (generally the vesting period). We estimated the fair value of each stock option or stock purchase warrant at the grant date by using the Black-Scholes option pricing model. See Note 7 for additional disclosures.

- 11 -

OMNI BIO PHARMACEUTICAL, INC. AND SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

Earnings (Loss) per Share

Basic earnings (loss) per share is computed based on the weighted average number of common shares outstanding during the period presented. In addition to common shares outstanding, and in accordance with FASB ASC Topic 260 Earnings per Share, any shares issuable for little or no cash consideration are considered outstanding shares as of the beginning of a reporting period and are included in the calculation of the weighted average number of common shares. Accordingly, for the nine months ended December 31, 2009, the weighted average number of common shares outstanding included 200,000 and 1,950,000 shares issuable under outstanding common stock purchase warrants (“warrants”) that were immediately exercisable at $0.01 and $0.001, respectively.

Diluted earnings (loss) per share is computed using the weighted average number of common shares outstanding plus the number of common shares that would be issued assuming exercise or conversion of all potentially dilutive common shares. Potentially dilutive securities are excluded from the calculation when their effect would be anti-dilutive. For all periods presented in the consolidated financial statements, all potentially dilutive securities have been excluded from the diluted share calculations as they were anti-dilutive as a result of the net losses incurred for the respective periods. Accordingly, basic shares equal diluted shares for all periods presented. For the three and nine months ended December 31, 2009, potentially dilutive securities were comprised of 10,750,200 common stock purchase warrants and 25,000 shares issuable upon conversion of a note payable. For the three and nine months ended December 31, 2008, potentially dilutive securities were comprised of 2,207,500 common stock purchase warrants and 25,000 shares issuable upon conversion of a note payable.

Recently Issued Accounting Standard Updates

We have reviewed all of the FASB’s Accounting Standard Updates through the filing date of this report, February 4, 2010, and have concluded that none will have a material impact on our future consolidated financial statements.

Subsequent Events

We have evaluated events subsequent to December 31, 2009 through the filing date of this report, February 4, 2010.

NOTE 2 - MERGER TRANSACTIONS

Apro Utah and Maxcure Merger

On March 31, 2008, Apro Utah and Maxcure completed a merger with Maxcure continuing as the surviving legal entity under the name of Apro Bio. The purpose of the merger was primarily one of synergies between the two companies in their efforts to continue funding sponsored research under their existing licensing relationships with UCD.

Under this merger, Maxcure issued to Apro Utah stockholders 11,726,562 of its common shares in exchange for all of the issued and outstanding shares of Apro Utah. Upon completion of the merger, former Apro Utah stockholders held 11,726,562 common shares (or approximately 64%) of the total 18,189,642 common shares issued and outstanding of Maxcure, and former Maxcure stockholders held 6,462,900 common shares (or approximately 36%). As a result of this majority ownership, Apro Utah was deemed the acquirer for accounting purposes and its historical financial statements have been adopted and presented for all periods in this report.

- 12 -

OMNI BIO PHARMACEUTICAL, INC. AND SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

In exchange for the issuance of its shares, Maxcure cancelled debt due from Apro Utah of $938,241 comprised of $804,692 of promissory notes and related accrued interest and other intercompany amounts of approximately $133,549. Also, warrants held by Maxcure stockholders to purchase 600,000 shares of Apro Utah were cancelled. Warrants to purchase 1,052,500 shares of Apro Utah common stock were converted to an equivalent number of warrants in the merged entity. Warrants to purchase 130,000 shares of Maxcure stock held by existing Maxcure stockholders were retained in the merged entity.

Assets acquired and liabilities assumed of Maxcure by Apro Utah on March 31, 2008 based on their estimated fair values were as follows:

Cash	$	6,750
Other current assets		272
Property and equipment		1,524
Licenses		22,972
Accounts payable		(31,518	)

Net assets acquired	$	-

Amounts assigned to licenses relate to respective patent filings made by UCD and are subject to amortization commensurate with the estimated patent life. The net unamortized amount of each license was deemed to be the fair value and was recorded at the date of the merger.

Apro Bio and Across America Merger

On March 31, 2009 and pursuant to the Merger among Across America, a non-operating public shell corporation, Apro Bio and AAAC, a wholly-owned subsidiary of Across America, Apro Bio was merged into Across America, with Across America being the surviving legal entity. The primary reasons for the Merger were to create an entity to provide Apro Bio additional opportunities to raise capital to further its development efforts with UCD and to provide Apro Bio and Across America investors a long-term, public trading market for their common stock. Across America issued a total of 18,210,295 shares of its common stock to the stockholders of Apro Bio in exchange for all of the issued and outstanding common stock of Apro Bio. Warrants to purchase 1,957,500 shares of Apro Bio common stock were converted to an equivalent number of warrants in Across America. A warrant to purchase 200,000 shares of Across America stock held by an existing Across America stockholder was retained as part of the Merger. This warrant was exercised on June 29, 2009. In addition, a note, convertible into 25,000 shares of the common stock of Apro Bio, was converted into a note convertible into 25,000 shares of Across America’s common stock on the same terms and conditions.

After the consummation of the Merger, the former Apro Bio stockholders held approximately 91% of the issued and outstanding shares of Across America. As a result of this majority ownership, Apro Bio was deemed the acquirer for accounting purposes, and the transaction was accounted for as a reverse acquisition. Further, we followed the current guidance of the SEC related to reverse mergers between a private company and a public shell company, and considered the reverse merger as equivalent to a reverse recapitalization. Accordingly, we recorded no goodwill in the Merger.

Assets acquired and liabilities assumed of Across America by Apro Bio on March 31, 2009 based on their estimated fair values were as follows:

Cash	$	5,000
Other current assets		1,500
Note payable – related party		(132,000	)

Net liabilities assumed	$	(125,500	)

For all periods presented, the financial statements of Apro Bio have been adopted as the historical financial statements of Omni. On May 27, 2009, we changed our name to Omni Bio Pharmaceutical, Inc.

- 13 -

OMNI BIO PHARMACEUTICAL, INC. AND SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

As a condition to the Merger, Apro Bio authorized the issuance of a warrant to an affiliate of Across America to purchase 200,000 shares of Apro Bio’s common stock at an exercise price of $0.001 per share. This warrant was exercised on June 29, 2009. In connection with the Merger, Across America paid an advisor fee to Bathgate Capital Partners, LLC (“BCP”) in the form of a warrant to purchase 1,750,000 shares of its common stock at an exercise price of $0.001 per share (the “Advisor Warrants”). During June and July 2009, all of the Advisor Warrants were exercised and we issued 1,750,000 shares of our common stock pursuant to those exercises.

The warrants issued in the Merger (the“Merger Warrants”) were valued using the Black-Scholes model with the following assumptions: exercise price of $0.001 per share, stock price of $1.00, expected life of five years (representing the full contractual term as prescribed by the SEC for investor warrants), expected volatility of 100%, risk-free interest rate of 1.82% (commensurate with the expected life) and dividend yield of 0%. The total amount of the charges recorded for the Merger Warrants was $1,948,237.

We evaluated the Merger Warrants as potential free standing derivatives under the criteria in FASB ASC Topic 815 Derivatives and Hedging (“Topic 815”), which requires that a contract issued by a reporting entity be accounted for as a derivative unless it is both (1) indexed to its own stock and (2) classified in stockholders’ equity in its statement of financial position. We concluded that the Merger Warrants were indexed to the Company’s own stock and should be classified in stockholders’ equity and would qualify for the scope exception contained in Topic 815. As further required, we reviewed the requirements for equity classification contained in Topic 815, and concluded that all of the criteria had been met and that equity classification was appropriate.

Warrant Modifications

On January 14, 2009, our board of directors (the “Board”) unanimously authorized the extension from March 31, 2010 to March 31, 2012 of 500,000 warrants that were previously issued to investors. The Board concluded that these warrants would expire prior to the expiration of lockup agreements required by Across America in conjunction with the Merger. The warrants that were extended by this resolution are exercisable at $1.10 per share, and include 80,000 warrants purchased by an outside director of the Company and 5,000 warrants purchased by the former CEO, President and director of the Company.

Also extended were 257,500 warrants issued to two unaffiliated investors that are exercisable at $1.00 per share, of which 250,000 were extended from May 10, 2010 to May 10, 2012 and 7,500 were extended from June 6, 2010 to June 6, 2012. Additionally, 30,000 warrants that were originally issued to a consultant and exercisable at $1.00 per share were extended from May 10, 2010 to May 10, 2012.

We accounted for these extensions as modifications to the original warrant grants as outlined in Topic 718. For the year ended March 31, 2009, we recorded a non-cash charge of $148,155 related to the investor warrants and share-based compensation of $25,843 related to the employee and consultant warrants, calculated as the difference between the estimated fair value of the warrant immediately prior to the modification and the estimated fair value of the warrant after the modification. Both values were calculated using the Black-Scholes model, with the revised exercise price and expected life of the warrant being the only change in the assumptions.

- 14 -

OMNI BIO PHARMACEUTICAL, INC. AND SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

NOTE 3 – PRIVATE PLACEMENT TRANSACTIONS

Private Placement – March 31, 2009

In conjunction with the Merger and also on March 31, 2009, we closed a private placement securities offering (the “Private Placement”) to four accredited investors. We issued units, consisting of one share of our common stock, a warrant to purchase one-half a share of our common stock at an exercise price of $0.25 per share (two warrants must be exercised to purchase one share of common stock), two warrants to purchase two shares of our common stock (one warrant purchases one share of common stock) at an exercise price of $0.50 per share and a warrant to purchase one share of our common stock at an exercise price of $1.00 per share (the “PP Units”). We sold the PP Units at a price of $1.00 per PP Unit and issued 1,870,000 PP Units for gross cash proceeds of $1,820,000 and the conversion of a note payable to a related party of $50,000. The warrants (the “Investor Warrants”) issued to investors in the Private Placement expire March 31, 2014.

The Investor Warrants that are exercisable at $0.25 and $0.50 per share are callable (the “Warrant Call”) through March 31, 2014 at our option. We may execute the Warrant Call by giving to the warrant holder a notice of call upon 20 days written notice (the "Call Notice"). A Call Notice may be given by the Company only within 10 days after our common stock has had a closing price of not less than $2.50 per share for 20 out of 30 consecutive trading days with trading volume in excess of 50,000 shares per day for that period of days.

In connection with the Private Placement, we paid to BCP a placement agent fee comprised of $112,200 in cash and a warrant to purchase 56,100 shares of our common stock at an exercise price of $0.25 per share, a warrant to purchase 224,400 shares of our common stock at $0.50 per share, and a warrant to purchase 224,400 shares of our common stock at $1.00 per share. We recorded a charge related to the issuance of these warrants (the “Placement Agent Warrants”) in the amount of $403,350 as calculated using the Black-Scholes model.

We evaluated both the Investor Warrants and the Placement Agent Warrants (collectively, the “Private Placement Warrants”) as potential free standing derivatives under the criteria in Topic 815, which requires that a contract issued by a reporting entity be accounted for as a derivative unless it is both (1) indexed to its own stock and (2) classified in stockholders’ equity in its statement of financial position. We concluded that the Private Placement warrants were indexed to the Company’s own stock and should be classified in stockholders’ equity and would qualify for the scope exception contained in Topic 815. As further required, we reviewed the requirements for equity classification contained in Topic 815, and concluded that all of the criteria had been met and that equity classification was appropriate.

A summary of the warrants issued in the Merger and the Private Placement is as follows:

Number of Warrants		Exercise Price		Estimated Fair Value Charge Recorded

	1,950,000	$	0.001	$	1,948,237
	991,100	$	0.25		49,842
	3,964,400	$	0.50		185,784
	2,094,400	$	1.00		167,904

	8,999,900			$	2,351,767

- 15 -

OMNI BIO PHARMACEUTICAL, INC. AND SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

Private Placement – December 2009 and January 2010

On December 29, 2009, we accepted subscription agreements related to the sale of Units in the PPO. Each “PPO Unit” was comprised of one share of our common stock and one warrant to purchase one share of our common stock for a purchase price of $2.50 per PPO Unit (the “PPO Warrants”). Each PPO Warrant is exercisable at $3.75 through December 29, 2014. The maximum amount of the PPO is $2.5 million or 1,000,000 PPO Units. The net proceeds from the PPO will be used to fund research and development and for general working capital purposes. We completed the PPO in multiple closings in January 2010 and completed the final closing on January 29, 2010 (the “Final Closing Date”). BCP served as the placement agent for the PPO and earned a commission of 8% plus a non-accountable expense allowance of 2% of the gross proceeds raised. In addition, we are obligated to sell for a nominal fee to BCP, as the placement agent, warrants to purchase 20% of the total number of PPO Units sold in PPO, half of which will be exercisable at a price of $2.50 per share and half of which will be exercisable at $3.75 per share (collectively, the “PPO PA Warrants”). The PPO PA Warrants expire five years from the Final Closing Date and are exercisable 180 days after the Final Closing Date.

At the Company’s option, we may call the PPO Warrants through December 29, 2014 by giving to the holder a notice of call upon 20 days written notice (the "PPO Call Notice"). A PPO Call Notice may be given by the Company only within 10 days after our common stock has had a closing price of not less than $6.00 per share for 20 out of 30 consecutive trading days with trading volume in excess of 25,000 shares per day for that period of days.

On December 29, 2009, we conducted the initial closing under the PPO, pursuant to which we entered into subscription agreements for the purchase of 146,000 PPO Units for an aggregate subscription price of $365,000. Additionally, on December 31, 2009, we entered into a subscription agreement for the purchase of 10,000 PPO Units for an aggregate subscription price of $25,000. After deducting offering expenses including commissions and expenses paid to the placement agent, net proceeds to the Company from such sales totaled $351,000.

In conjunction with the initial closing of the PPO, we sold for a nominal fee to BCP, as the placement agent, PPO PA Warrants to purchase 15,600 shares of our common stock at an exercise price of $2.50 per share and 15,600 shares of our common stock at an exercise price of $3.75 per share. We calculated the value of these PPO PA Warrants at $69,962 using the Black-Scholes model and recorded this amount as a charge to additional paid in capital.

We evaluated both the PPO Warrants and the PPO PA Warrants as potential free standing derivatives under the criteria in Topic 815. We concluded that the both the PPO Warrants and the PPO PA Warrants were indexed to the Company’s own stock and should be classified in stockholders’ equity and would qualify for the scope exception contained in Topic 815. As further required, we reviewed the requirements for equity classification contained in Topic 815, and concluded that all of the criteria had been met and that equity classification was appropriate.

NOTE 4– RELATED PARTIES AND DEBT OBLIGATIONS

Convertible Note Payable – Related Party

On May 30, 2008, we entered into a $25,000 unsecured, convertible debenture agreement with the spouse of a director and related party (the “Bathgate Note”). The Bathgate Note bears interest at 6%, is convertible into our common stock at $1.00 per share and matures June 30, 2010. As additional consideration, we issued a warrant to purchase 50,000 shares of our common stock at $1.00 per share (the “Bathgate Warrant”), which expires on June 30, 2013. In addition, this warrant included a reset provision, which provided, that if we issued a similar security with common stock purchase warrants exercisable below $1.00 per share, the exercise price would be reduced to the lower price. This reset provision pertained to any new investment made prior to December 31, 2008 and expired effective with the completion of the Private Placement.

- 16 -

OMNI BIO PHARMACEUTICAL, INC. AND SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

We concluded that the Bathgate Note met the definition of “conventional convertible debt,” as defined in Topic 815, as the note holder may only realize the value of the conversion option by converting the note and receiving the entire proceeds in a fixed number of shares or the equivalent amount of cash (at the discretion of the Company). Further, we concluded that the conversion option of the Bathgate Note represented an embedded derivative as defined in Topic 815 and was indexed to the Company’s common stock. Therefore, we concluded that the conversion feature of the Bathgate Note did not meet the definition of a derivative under Topic 815 and did not require separate accounting from the debt instrument.

In accordance with FASB ASC Topic 470-20 Debt with Conversion and Other Options (“Topic 470-20”), we allocated the cash proceeds received to both the Bathgate Note and Bathgate Warrants based on relative fair values of each. We valued the warrant using the Black-Scholes model with the following assumptions: exercise price of $1.00 per share, stock price of $1.00, expected life of five years (representing the full contractual term as prescribed by the SEC for investor warrants), expected volatility of 95%, risk-free interest rate of 2.45% (commensurate with the expected life) and dividend yield of 0%. The value assigned to the Bathgate Warrant was $14,830 and was credited to additional paid-in capital with a corresponding debt discount recorded as a reduction to the Bathgate Note.

We further concluded that the conversion feature in the Bathgate Note met the definition of a “beneficial conversion feature” as outlined in Topic 470-20. The amount of proceeds allocated to the Bathgate Note was $10,170 (calculated as the $25,000 principal less the discount related to the value assigned to the Bathgate Warrants of $14,830 per above), which resulted in an effective conversion price of $0.41 per share and an intrinsic value of $0.59 per share (calculated as $1.00 conversion price less $0.41 effective conversion price). Therefore, the value assigned to the beneficial conversion feature was $10,170, which represented the initial amount allocated to the Bathgate Note, and was recorded as an additional debt discount to the note with a corresponding credit to additional paid-in capital. In accordance with Topic 470-20, the amount recorded for the beneficial conversion feature was limited to the amount of proceeds allocated to the convertible instrument of $10,170. This resulted in a full discount offset to the $25,000 principal balance of the note, or an initial carrying value of $-0-. We are accreting the discount over the life of the note.

We also evaluated the Bathgate Warrant as a potential free standing derivative under the criteria in Topic 815, and concluded that it was indexed to the Company’s own stock and should be classified in stockholders’ equity and would qualify for the scope exception contained in Topic 815. As further required, we reviewed the requirements for equity classification contained in Topic 815, and concluded that all of the criteria had been met and that equity classification was appropriate.

Pursuant to the reset provision described above, on November 6, 2008, the exercise price on the Bathgate Warrant was reduced to $0.50 per share with all other terms remaining intact. This reset was a result of a bridge loan entered into on that date with BOCO Investments, LLC (“BOCO”) (the “BOCO Note”), a related party to Across America. We recorded a charge for the modification of the exercise price on the Bathgate Warrant in the amount of $4,531, which was calculated as the difference between the estimated fair value of the warrant immediately prior to the modification and the estimated fair value of the warrant after the modification. Both values were calculated using the Black-Scholes model with the revised exercise price being the only difference in the assumptions.

Note Payable – BOCO Investments, LLC

On November 6, 2008, we executed the BOCO Note, pursuant to which BOCO loaned $50,000 at an interest rate of 12% per annum in the form of a note, which was collateralized by substantially all of our assets. As additional consideration for the BOCO Note, we issued to BOCO a warrant (the “BOCO Warrant”) to purchase 100,000 shares of our common stock. This warrant is exercisable at $0.50 per share and expires on December 31, 2013. The BOCO Note was originally due on February 4, 2009 and was converted into equity as part of the Private Placement.

- 17 -

OMNI BIO PHARMACEUTICAL, INC. AND SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

We allocated the cash proceeds received to both the BOCO Note and the BOCO Warrant based on relative fair values of each. We valued the warrant using the Black-Scholes model with the following assumptions: exercise price of $0.50 per share, stock price of $1.00, expected life of five years (representing the full contractual term as prescribed by the SEC for investor warrants), expected volatility of 100%, risk-free interest rate of 0.32% (commensurate with the expected life) and dividend yield of 0%. The value assigned to the BOCO Warrant was $31,125 and was credited to additional paid-in capital with a corresponding debt discount recorded as a reduction to the BOCO Note. We accreted this debt discount over the life of the note, but upon conversion of the note pursuant to terms in the Private Placement, we wrote-off the remaining unamortized discount as of March 31, 2009.

Other Obligations

On May 31, 2008, the Chief Executive Officer and President of Apro Bio resigned from these positions and on October 1, 2008, resigned as a director of Apro Bio. On March 3, 2009, we entered into a settlement agreement with this individual and agreed to settle any and all claims for a lump sum payment of $45,000 and the issuance of 60,000 shares of our common stock.

NOTE 5 – COMMITMENTS AND CONTINGENCIES

License Agreement with Bio Holding, Inc.

On September 28, 2009 (the “Effective Date”), we entered into a license agreement with Bio Holding, Inc. (“Bio Holding”) pursuant to which we obtained an exclusive license (the “License Agreement”) to practice, perform, make, use, sell, import and offer to sell products covered by current and future patents and patent applications owned by Bio Holding for the treatment of diabetes (the “Licensed Technology”). We may not sublicense, assign or otherwise transfer its rights in the Licensed Technology without the prior written consent of Bio Holding. In addition, we have a right of first refusal to license any intellectual property owned by Bio Holding that is not part of the License Agreement. Dr. Leland Shapiro, who is the beneficial owner of approximately 14% of our common stock, is the majority shareholder of Bio Holding.

In consideration for the License Agreement, we were obligated to pay Bio Holding within 60 days from the Effective Date a license fee of $25,000. We paid this amount in November 2009. As additional consideration, we issued to a minority shareholder of Bio Holding warrants to purchase 650,000 shares of our common stock at an exercise price of $3.00 per share. The warrants expire on September 28, 2014 and contain a cashless exercise provision. Such warrants were subject to the execution of a subscription and lock-up agreement by the minority shareholder that restricts the sale or transfer of the underlying shares until March 31, 2011. We estimated the fair value of the warrants at $1,470,000, which was calculated using the Black-Scholes model with the following assumptions: exercise price of $3.00 expected life of five years, assumed stock price of $3.00 at date of grant, dividend yield of 0%, interest rate of 2.72%, and volatility of 100.0%. The total value ascribed to this license agreement was $1,495,000, and we expensed this amount for the three months ended September 30, 2009.

We are obligated to pay royalties to Bio Holding of (i) four percent (4%) of the gross revenues from the sale or use of the Licensed Technology and (ii) thirty percent (30%) of the gross revenues from sublicensing of the Licensed Technology. We were also obligated to enter into an SRA with UCD for the benefit of Dr. Leland Shapiro’s laboratory. As of December 31, 2009, we had not executed the SRA, which is expected to be in the amount of $88,000.

- 18 -

OMNI BIO PHARMACEUTICAL, INC. AND SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

The term of the License Agreement expires upon the expiration date of the last patent underlying the Licensed Technology. The License Agreement may be terminated only upon the material breach of the terms and conditions of the License Agreement by the other party, subject to a 30 day cure period. During the term of the License Agreement, we will bear all expenses related to filing, prosecuting and maintaining the patents and patent applications underlying the Licensed Technology, including, but not limited to, expenses related to divisional, continuation-in-part patent applications and foreign filings.

Bacterial Infection License

As of December 31, 2009, our current commitments under our SRA associated with this license was $81,300, which was paid in January 2010.

Pursuant to a stock purchase agreement, which was executed on May 15, 2006 simultaneously with the license agreement and the SRA, during the quarter ended June 30, 2008, we issued to a designee and beneficiary of RUC, University License Equity Holdings, Inc. (“ULEHI”), 20,833 shares of our common stock. In conjunction with the issuance of the license for cell transplant/graft rejection on November 12, 2008, we agreed to amend the terms of the stock purchase agreement with ULEHI by authorizing the issuance of additional shares of our common stock, calculated at 2% of the fully-diluted outstanding shares of our common stock upon completion of the Merger. The calculation of these shares included all common shares and common stock purchase warrants issued in connection with the Merger and the Private Placement. In accordance with this provision, we issued 698,939 shares of our common stock to ULEHI.

We have no further obligations for common share issuances to ULEHI under any of the three license agreements.

Viral Infection License

As of December 31, 2009, we had not executed an SRA related to this license.

Cellular Transplant/Graft Rejection

As of December 31, 2009, we had not executed an SRA related to this license.

- 19 -

Future royalty payments under license agreements are summarized below:

License Date	Field of Use	Minimum Royalties	Milestone Royalties	Earned Royalties	Sublicense Royalties

May 15, 2006	Bacterial	$25,000 per year starting May 15, 2011	$30,000 to $300,000 (1)	4% of Net Sales	20% to 30%

March 30, 2008	Viral (including HIV)	$50,000 per year after first commercial sale	$100,000 to $150,000 (2)	4% of Net Sales	20% to 30%

November 12, 2008	Cellular Transplant /Graft Rejection	$50,000 per year after first commercial sale	$25,000 to $200,000 (3)	3% of Net Sales	20% to 30%

September 28, 2009	Diabetes	None	None	4% of Gross Revenues (4)	30% (4)

________________

(1) Payable to RUC as follows: $30,000 upon completion of preclinical trial; $50,000 upon completion of a phase I clinical trial; $100,000 upon completion of a phase II clinical trial; $200,000 upon completion of a phase III clinical trial; and $300,000 upon receipt of approval of FDA or foreign equivalent.

(2) Payable to RUC as follows: $100,000 upon completion of any phase III clinical trial and $150,000 upon first commercial sale. No milestone royalties are required for the first indication. For the second indication, 100% of the milestone royalties shall be paid, and for subsequent indications 50% of the milestone royalties shall be paid.

(3) Payable to RUC as follows: $25,000 upon initiation of a phase II clinical trial; $100,000 upon initiation of a phase III clinical trial; and $200,000 upon receipt of approval of FDA or foreign equivalent.

(4) Payable to Bio Holding.

The license agreements expire upon the expiration date of the last patent covered by the agreement and may also be terminated by either party in the event of a default by the other party.

Contributed Rent

We utilize, free-of-charge, office space of BCP, a shareholder and related party. We calculated the value of our approximate utilized office space at $1,260 for each of the quarters ended June 30, September 30 and December 31, 2009 and $2,100 for each of the quarters ended June 30, September 30 and December 31, 2008, and recorded non-cash charges for these amounts in the respective periods.

NOTE 6 – STOCKHOLDERS’ EQUITY

On May 27, 2009, we filed Articles of Amendment to our Articles of Incorporation to change our corporate name from “Across America Financial Services, Inc.” to “Omni Bio Pharmaceutical, Inc.” At the same time, we also filed Articles of Amendment to our Articles of Incorporation to increase our authorized common shares to 200,000,000 from 50,000,000 and to increase our authorized preferred shares to 5,000,000 from 1,000,000. The par values of the common and preferred shares were not changed.

For the quarter ended June 30, 2009, we issued 600,000 shares of our common stock pursuant to the conversion of a note payable to a related party. Additionally, we issued 1,375,356 shares of our common stock pursuant to warrant exercises by related parties, which were comprised of 1,175,356 warrants exercised for $0.001 per share and 200,000 warrants exercised for $0.01 per share, generating $3,175 of net cash proceeds. In addition, we issued 126,097 shares of common stock pursuant to cashless exercise provisions of 140,000 warrants exercised at a weighted average price of $1.09 per share.

- 20 -

OMNI BIO PHARMACEUTICAL, INC. AND SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

For the quarter ended September 30, 2009, we issued 1,260,031 shares of our common stock pursuant to warrant exercises by related parties, which were comprised of 774,644 warrants exercised for $0.001 per share for cash proceeds of $775 and 485,387 shares issued pursuant to cashless provisions of 515,900 warrants exercised at a weighted average price of $0.75 per share. In addition, we issued 268,720 shares of common stock pursuant to cashless exercise provisions of 290,000 warrants exercised at a weighted average price of $1.10 per share.

For the quarter ended December 31, 2009, we issued 291,714 shares of our common stock pursuant to cashless exercise provisions of 317,500 warrants exercised at a weighted average price of $1.02 per share. In addition, we recorded a charge in the amount of $528,000 related to a modification of 250,000 warrants that were exercised in the December 2009 quarter. The estimated fair value of the modification was calculated using the Black-Scholes model.

As discussed in Note 3, on December 29 and 31, 2009 and under the PPO, we issued to PPO investors 156,000 shares of our common stock and warrants to purchase 156,000 shares of our common stock, exercisable at $3.75 per share through December 29, 2014, resulting in net cash proceeds to the Company of $351,000. We also sold for a nominal fee to the placement agent warrants to purchase 15,600 shares of our common stock at an exercise price of $2.50 per share and 15,600 shares of our common stock at an exercise price of $3.75 per share. The placement agent warrants expire five years from the Final Closing Date and are exercisable 180 days after the Final Closing Date.

A summary of investor warrant activity for the nine months ended December 31, 2009 was as follows:

	Number of Warrants

Outstanding and exercisable at March 31, 2009		10,107,400
Issued – pursuant to license agreement with Bio Holding		650,000
Issued – pursuant to the PPO		187,200
Exercised		(3,287,400	)
Forfeited/expired		-
Outstanding and vested at December 31, 2009		7,657,200

Exercisable at December 31, 2009		7,626,000

NOTE 7 – SHARE-BASED COMPENSATION

From inception, we have not had an employee stock option plan, but have issued common stock purchase warrants on a discretionary basis to employees, directors and outside consultants. We calculate share-based compensation to employees and directors in accordance with the fair-value method prescribed in Topic 718. For warrants issued to outside consultants (i.e., non-employees), we calculate share-based compensation under the applicable provisions of Topic 718 and FASB ASC Topic 505-50 Equity-Based Payments to Non-Employees (“Topic 505-50”). Topic 718 requires fair value accounting for equity securities issued to non-employees, and Topic 505-50 specifies the measurement date for recording compensation cost.

For warrants issued in the nine months ended December 31, 2009 and 2008, the fair value of each warrant award was estimated on the date of grant using the Black-Scholes pricing model based on assumptions noted in the following table. The expected life was equal to the contractual term, as the majority of all warrants granted are not forfeited in the circumstances of disassociation with the Company. Expected volatility was estimated based on comparisons of stock price volatility of “peer group” publicly-traded companies. The risk-free interest rate was based on the yield on the grant measurement date of a traded zero-coupon U.S. Treasury bond, as reported by the U.S. Federal Reserve, with a term equal to the expected term of the respective warrant.

- 21 -

OMNI BIO PHARMACEUTICAL, INC. AND SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

The following table provides the range of assumptions used in the Black-Scholes pricing model for warrants granted during the nine months ended December 31, 2009 and 2008, respectively:

	December 31, 2009		December 31, 2008

Expected life (years)	5.0 to 7.0			7.0
Expected volatility		100%		100.5%
Risk-free interest rate	1.86 to 3.37%		2.1 to 3.03%
Dividend yield		0%		0%

Issuances for the Three Months Ended June 30, 2009

On April 7, 2009, we granted a warrant to our acting chief executive officer to purchase 600,000 shares of our common stock at an exercise price of $0.50 per share. Shares under this warrant vest as follows: 200,000 upon issuance, 200,000 in October 2009 and 200,000 in April 2010. We are recognizing share-based compensation using the straight-line method over the vesting term of the grant. This warrant expires on April 7, 2016. We valued these warrants at $529,975 using the Black-Scholes model with the following assumptions: exercise price of $0.50 expected life of seven years, assumed stock price of $1.00 at date of grant, dividend yield of 0%, interest rate of 2.47%, and volatility of 100.0%.

On April 15, 2009, we granted a warrant to our chief financial officer to purchase 50,000 shares of our common stock at an exercise price of $0.50 per share. All shares under this warrant vested upon issuance. This warrant expires on April 15, 2016. We valued this warrant at $44,165 using the Black-Scholes model with the following assumptions: exercise price of $0.50 expected life of seven years, assumed stock price of $1.00 at date of grant, dividend yield of 0%, interest rate of 2.47 %, and volatility of 100.0%.

On April 1, 2009, we granted a warrant to a medical consultant to purchase 48,000 shares of our common stock at an exercise price of $1.25 per share. All shares under this warrant vested as of September 30, 2009. This warrant expires on April 1, 2014. For the six months ended September 30, 2009, we recorded a charge for share-based compensation using the straight-line method over the vesting term of the grant of $35,927. We valued this warrant at $35,927 using the Black-Scholes model with the following assumptions: exercise price of $1.25, expected life of five years, assumed stock price of $1.00 at date of grant, dividend yield of 0%, interest rate of 2.47 %, and volatility of 100.0%.

Issuances for the Three Months Ended September 30, 2009

On July 30, 2009 and pursuant to our compensation program for directors (whereby a director receives a grant of 100,000 warrants in the first year of service and 50,000 warrants per year for each subsequent year of service), we granted warrants to our directors (excluding our acting CEO who is a director) to purchase 275,000 shares of our common stock in exchange for director services for the fiscal year ended March 31, 2010 (the “Director Warrants”). The Director Warrants were granted at an exercise price of $3.00 per share, which represented management’s estimated fair value of our common stock price as of the date of grant based on factors, including, but not limited to: 1) initial discussions with potential investors on an equity capital raise at a price of $3.00 per share, 2) the limited trading volume and limited public trading duration of our common stock, 3) recent private common stock sale transactions, and 4) the trading lock-up requirement of two or three years on the majority of our outstanding warrants and common stock. Four of the directors received an annual grant of 50,000 warrants based on the commencement of their second year of service, which was April 1, 2009. Warrants under these grants vest on March 31, 2010 and expire on April 1, 2016. A fifth director received a grant of 25,000 warrants for the fourth quarter of his first year of service. Warrants under this grant vested April 1, 2009 and expire on April 1, 2016. A sixth director received a grant of 50,000 warrants for the third and fourth quarters of his first year of service, of which 25,000 vested April 1, 2009 and expire on April 1, 2016 and 25,000 vest on July 1, 2009 and expire on July 1, 2016.

- 22 -

OMNI BIO PHARMACEUTICAL, INC. AND SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

We valued these warrants at $688,908 using the Black-Scholes model with the following assumptions: exercise price of $3.00, expected life of seven years, estimated fair value of our common stock price of $3.00 at date of grant, dividend yield of 0%, interest rate of 3.37 %, and volatility of 100.0%. For the three months ended June 30, 2009, we recorded a charge for share-based compensation and a liability for accrued compensation in the amount of $250,512 for director services provided during the quarter. The amount of the charge represented the estimated fair value of 50,000 Director Warrants that vested as of April 1, 2009 and 25% (based on the straight-line method) of the estimated fair value of 200,000 Director Warrants that will vest on March 31, 2010.

Pursuant to Board approval on July 30, 2009, on August 6, 2009 we granted 50,000 common stock purchase warrants exercisable at $3.00 per share and expiring on August 6, 2016 to a director for a second year of service. The warrants vest on August 5, 2010 if the director has continuously served as a director of the Company through such date. We valued these warrants at $125,256 using the Black-Scholes model with the following assumptions: exercise price of $3.00, expected life of seven years, estimated fair value of our common stock price of $3.00 at date of grant, dividend yield of 0%, interest rate of 3.14% and volatility of 100.0%.

Issuances for the Three Months Ended December 31, 2009

Pursuant to Board approval on July 30, 2009, on October 1, 2009, we granted 50,000 common stock purchase warrants exercisable at $3.00 per share and expiring on October 1, 2016 to a director for his second year of service. The warrants vest on September 30, 2010 if the director has continuously served as a director of the Company through such date. We valued these warrants at $124,854 using the Black-Scholes model with the following assumptions: exercise price of $3.00, expected life of seven years, estimated fair value of our common stock price of $3.00 at date of grant, dividend yield of 0%, interest rate of 3.02% and volatility of 100.0%.

On October 12, 2010, our Board appointed a new director to our Board as a result of a resignation of a Board director. All previously recorded share-based compensation related to the unvested warrants held by this director was reversed in the December 2009 quarter. Also on October 12, 2009, we granted 100,000 common stock purchase warrants exercisable at $3.00 per share and expiring on October 12, 2016 to the new director for his first year of service as a director. The warrants vest on October 11, 2010 if the director has continuously served as a director of the Company through such date. We valued these warrants at $249,709 using the Black-Scholes model with the following assumptions: exercise price of $3.00, expected life of seven years, estimated fair value of our common stock price of $3.00 at date of grant, dividend yield of 0%, interest rate of 3.02% and volatility of 100.0%.

On October 12, 2009 and as consideration for consulting service agreements that we executed with a director and a member of our scientific advisory board, we granted to these two individuals 50,000 and 100,000 common stock purchase warrants, respectively, exercisable at $3.00 per share and expiring October 12, 2014. The warrants vest on October 11, 2010 if the individual has continuously provided service to the Company through such date. We valued these warrants at $338,272 using the Black-Scholes model with the following assumptions: exercise price of $3.00, expected life of five years, estimated fair value of our common stock price of $3.00 at date of grant, dividend yield of 0%, interest rate of 2.37% and volatility of 100.0%.

On December 16, 2009, our Board approved the grant to our acting chief executive officer of 600,000 common stock purchase warrants exercisable at $3.00 per share and expiring on November 13, 2016. The warrants vest and become exercisable in four equal installments on March 31, 2010, March 31, 2011, March 31, 2012 and March 31, 2013, subject to continuous service with the Company. We valued these warrants at $1,498,251 using the Black-Scholes model with the following assumptions: exercise price of $3.00, expected life of seven years, estimated fair value of our common stock price of $3.00 at date of grant, dividend yield of 0%, interest rate of 2.92% and volatility of 100.0%.

- 23 -

OMNI BIO PHARMACEUTICAL, INC. AND SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

On December 16, 2009, our Board approved the grant to our chief financial officer of 300,000 common stock purchase warrants exercisable at $3.00 per share and expiring on November 13, 2016. The warrants vest and become exercisable as follows: 60,000 shares on November 20, 2009, 80,000 shares on September 30, 2010, 80,000 shares on September 30, 2011, and 80,000 shares on September 30, 2012, all subject to continuous service with the Company. We valued these warrants at $749,126 using the Black-Scholes model with the following assumptions: exercise price of $3.00, expected life of seven years, estimated fair value of our common stock price of $3.00 at date of grant, dividend yield of 0%, interest rate of 2.92% and volatility of 100.0%.

As of December 31, 2009, we recorded $9,999 in share-based compensation for shares of our common stock to be issued pursuant to a consulting agreement that we executed during the December 2009 quarter.

Share-based compensation recorded for the three and nine months ended December 31, 2009 and 2008 was as follows:

	Three months ended December 31,				Nine months ended December 31,
	2009		2008		2009		2008

Employees, former employees and directors	$	503,575	$	122,372	$	1,183,670	$	428,184
Outside consultants		94,567		-		130,494		-

	$	598,142	$	122,372	$	1,314,164	$	428,184

The weighted average grant date fair value of warrants issued under share-based compensation agreements for the nine months ended December 31, 2009 and 2008 was $1.97 and $0.82 per share, respectively.

A summary of warrant activity related to warrants issued under share-based compensation agreements for the nine months ended December 31, 2009 is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (a)

Outstanding at March 31, 2009		1,050,000		$	1.22
Granted		2,223,000		$	2.23
Exercised		(130,000	)	$	1.08
Forfeited/expired/cancelled		(50,000	)	$	3.00

Outstanding at December 31, 2009		3,093,000		$	1.92		5.9	$	3,330,000

Vested and exercisable at December 31, 2009		1,553,000		$	1.15		5.3	$	2,830,000

(a) Calculated using the estimated fair value of our common stock price as of December 31, 2009.

- 24 -

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Information May Prove Inaccurate

Some of the information presented in this Quarterly Report on Form 10-Q constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements that include terms such as “may,” “will,” “intend,” “anticipate,” “estimate,” “expect,” “continue,” “believe,” “plan,” or the like, as well as all statements that are not historical facts. Forward-looking statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from current expectations. Although we believe our expectations are based on reasonable assumptions within the bounds of our knowledge of our business and operations, there can be no assurance that actual results will not differ materially from expectations.

For additional factors that could affect the validity of our forward-looking statements, you should read the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2009 and the consolidated financial statements contained therein, as well as those set forth in Part II. – Item 1A of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. The forward-looking statements included in this quarterly report are subject to additional risks and uncertainties not disclosed in this quarterly report, some of which are not known or capable of being known by us. The information contained in this quarterly report is subject to change without notice. Readers should review future reports that we file with the SEC. In light of these and other risks, uncertainties and assumptions, actual events or results may be very different from those expressed or implied in the forward-looking statements in this quarterly report or may not occur. We have no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Organization

On March 31, 2009, Across America Financial Services, Inc. (“Across America”) completed the acquisition of Apro Bio Pharmaceutical Corporation (“Apro Bio”) pursuant to the terms of the Agreement of Merger and Plan of Reorganization, as amended (the "Merger”), among Across America, Apro Bio and Across America Acquisition Corp. (“AAAC”), a Colorado corporation and a wholly-owned subsidiary of Across America. Under the terms of the Merger, Apro Bio was merged into AAAC, and Apro Bio became a wholly-owned subsidiary of the Company. On May 27, 2009, Across America changed its name to Omni Bio Pharmaceutical, Inc. (“Omni”).

The Merger was accounted for as a reverse acquisition with Apro Bio being treated as the acquirer for accounting purposes. Accordingly, for all periods presented in this report, the financial statements of Apro Bio have been adopted as the historical financial statements of Omni.

Except as the context otherwise requires, the terms "Company," "we," "our, "us" or “Omni,” means Omni and our wholly-owned subsidiary, Omni Bio Operating, Inc.

Plan of Operation

We intend to commercialize a broad patent portfolio licensed from the as the University of Colorado Denver (“UCD”), formerly known as the University of Colorado Health Sciences Center (“UCHSC”). A component of these applications involves use of existing FDA approved drugs to treat a variety of bacterial and viral diseases, and transplant rejection in a subject.

We are the licensee of applications and patents related to novel compositions of matter and methods of use for an existing FDA approved drug, Alpha 1-Antitrypsin (“AAT”), for treating transplantation rejection, including islet cell transplantation for the treatment of diabetes, and treating bacterial infections including bacterial pneumonia, tuberculosis and anthrax. We have also licensed an existing patent for the treatment of HIV, and licensed patent applications for the treatment of other viral-associated disorders including influenza.

- 25 -

To date, our business efforts have been largely dedicated to pursue additional capital in order to continue funding Sponsored Research Agreements (“SRAs”) to further our licenses regarding bacterial disease treatments, and in funding SRAs for the furtherance of our licenses regarding viral disease treatment and cellular transplantation/graft rejection.

We have licensed and plan to further develop novel therapies for the treatment of medical conditions that we believe have the potential to move through clinical trials quickly. We also plan to shepherd these novel therapeutic applications through the FDA approval processes and advance them through commercialization. This core strategy is based on licensing issued patents and patent applications, partially directed to the use of an existing FDA approved drug that has come off of its initial patents for new and novel uses in treating disorders.

We intend to continue to outsource the normally capital intensive scientific research function to academic research institutions such as UCD, where we currently have one SRA. This approach provides a specific scientific budget for funding each application, without the possibility of substantial cost overruns being incurred internally. Work contracted with UCD or other research institutions is expected to provide a contractually guaranteed work product, greatly increasing our ability for financial forecasting. With this approach, we expect to be able to focus on working with each project's lead scientists, overseeing patent application projects and closely managing our corporate overhead. This approach should allow most of our expenses to be focused on research and development. Future research essential for developing these strategies will be conducted in accordance with our world-wide licensing rights and our existing and pending collaborative SRAs with UCD.

Recent Scientific Developments

Clinical Trial on Type I Diabetes

In December 2009, we received the approval of a protocol related to a proposed trial of AAT on patients diagnosed with Type I diabetes from the regional Institutional Review Board (“IRB”) at a unit of the University of Colorado-Denver-Anschutz Medical Campus. Subsequent to this approval, we filed with the FDA an Investigational New Drug Application (“IND”) for the use of AAT on Type I diabetes and to sponsor a clinical trial. AAT has received prior FDA approval as a biological treatment of emphysema. However, there is no assurance that the FDA will approve this clinical trial, and if the clinical trial is successful, there is no assurance that we will obtain FDA approval for the use of AAT to treat Type I diabetes in humans. Additionally, there is no assurance that, if approved, we will have available resources to complete the clinical trial in a timely manner or at all.

Bacterial License and Associated Sponsored Research Agreement

We have completed all of our payments under this SRA. Concurrently with this work, we are continuing to pursue our patent rights on patent applications directed to targeting bacterial disorders with the United States Patent and Trade Office (“USPTO”) as well as international offices.

Viral License and Viral Sponsored Research Agreement

We are currently negotiating an SRA related to our licensed and issued patent related to AAT and novel compositions for treating viral-related disorders. We expect that upon consummation of the SRA, we will be obligated to expend approximately $55,000 quarterly for a period of two years. Additionally, we are continuing to pursue patent rights based on our patent applications directed to treating viral-related disorders with the USPTO.

Cellular Transplant/Graft Rejection License and Associated Sponsored Research Agreement:

We are presently negotiating an SRA related to this license. Additionally, we are continuing to pursue patent rights based on our patent applications directed to related cellular transplant/graft rejection with the USPTO as well as foreign offices.

- 26 -

License Agreement with Bio Holding, Inc. (Treatment of Diabetes)

On September 28, 2009, we entered into a license agreement (the “License Agreement”) with Bio Holding, Inc. (“Bio Holding”) pursuant to which we obtained an exclusive license to practice, perform, make, use, sell, import and offer to sell products covered by current and future patents and patent applications owned by Bio Holding for the treatment of diabetes (the “Licensed Technology”). We also agreed to enter into an SRA with UCD for $88,000, which we are currently negotiating.

We may not sublicense, assign or otherwise transfer its rights in the Licensed Technology without the prior written consent of Bio Holding. In addition, we have a right of first refusal to license any intellectual property owned by Bio Holding that is not part of the license Agreement. Dr. Leland Shapiro, who is the beneficial owner of approximately 14.4% of our common stock, is the majority shareholder of Bio Holding.

Liquidity and Capital Resources

Our unaudited consolidated financial statements as presented in Item 1 of this report have been prepared in conformity with US GAAP, which contemplate our continuation as a going concern. However, the report of our independent registered public accounting firm on our consolidated financial statements, as of and for the year ended March 31, 2009, contains an explanatory paragraph expressing substantial doubt as to our ability to continue as a going concern. The “going concern” qualification results from, among other things, our development-stage status, no revenue recognized since inception, our inception to date net losses, which total approximately $11.0 million and include non-cash charges of approximately $7.7 million through December 31, 2009, and the outstanding and currently anticipated contractual commitments for research and development efforts under any current or anticipated SRAs. Our consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary if we were unable to continue as a going concern.

December 2009 and January 2010 Private Placement

In December 2009 and January 2010, we enhanced our liquidity with the first closing of a private placement equity offering (the “PPO”), which generated net cash of $351,000 (after offering costs of $39,000). In January 2010, we completed two additional closings of the PPO and generated net cash of $1,435,650 (after offering costs of $160,000).

Under the PPO, we sold “Units” (“PPO Units”), which were comprised of one share of our common stock and one warrant to purchase one share of our common stock for a purchase price of $2.50 per PPO Unit (the “PPO Warrants”). Each PPO Warrant is exercisable at $3.75 through December 29, 2014. The maximum amount of the PPO is $2.5 million or 1,000,000 PPO Units. The net proceeds from the PPO will be used to fund research and development and for general working capital purposes. We completed the PPO in multiple closings during January 2010 and completed the final closing on January 29, 2010 (the “Final Closing Date”). BCP served as the placement agent for the PPO and earned a commission of 8% plus a non-accountable expense allowance of 2% of the gross proceeds raised. In addition, we are obligated to sell for a nominal fee to BCP, as the placement agent, warrants to purchase 10% of the total number of PPO Units sold in PPO, half of which will be exercisable at a price of $2.50 per share and half of which will be exercisable at $3.75 per share (collectively, the “PPO PA Warrants”). The PPO PA Warrants expire five years from the Final Closing Date and are exercisable 180 days after the Final Closing Date.

- 27 -

We believe that the capital raised in the PPO provides us cash to fund our current operations and research and development for the near term. Depending on the extent that we increase research and development through potential new licenses or pursue clinical trials in addition to our current budgeted one, we will likely need to raise additional capital through additional equity financings or through other means that we deem necessary. There is no assurance that we will be successful in raising additional capital on acceptable terms or at all. Further, even if we raise additional capital, there is no assurance that we will raise sufficient capital to fund our operations.

Cash and Cash Flows

Our cash and cash equivalents at December 31, 2009 were $790,292 as compared to $1,805,395 at March 31, 2009 and $8,416 at December 31, 2008. For the nine months ended December 31, 2009, net cash used in operations was $1,370,053 as compared to net cash used in operations of $48,492 for the nine months ended December 31, 2008. For the nine months ended December 31, 2009, the primary uses of cash were for general and administrative expenses (excluding share-based compensation) of approximately $618,000 and a significant decrease from March 31, 2009 to December 31, 2009 of approximately $743,000 in accounts payable, accrued liabilities and amounts due to related parties. The significant decrease in these liabilities was a result of a significant pay-down on these liabilities that had largely been incurred during the first nine months of fiscal year 2009 because the Company had negligible cash on hand during fiscal year 2009 to settle liabilities on reasonable and, as applicable, contractual payment terms. For the nine months ended December 31, 2008, the primary use of cash was for general and administrative expenses (excluding share-based compensation) of approximately $333,000, and the primary sources of cash were net increases of approximately $321,000 from March 31, 2008 to December 31, 2008 in the amounts due to UCD under the bacterial SRA and net increases of approximately $201,000 in the aggregate of accounts payable, accrued liabilities and amounts due to related parties. The significant increase in these liabilities was attributable to negligible cash on hand during the nine months ended December 31, 2008.

For the nine months ended December 31, 2009, we did not generate or expend any cash from investing activities. For the nine months ended December 31, 2008, we used cash of $35,401 for the purchase of a license from UCD for cellular transplant/graft rejection. For the nine months ended December 31, 2009, net cash provided by financing activities was $354,950 and was primarily attributable to the net cash proceeds generated from the PPO in December 2009. For the nine months ended December 31, 2008, net cash provided by financing activities was $75,000 from notes payable executed with related parties.

Contractual Obligations

As previously disclosed under this item, we have an obligation to pay $88,000 under an SRA related to the License Agreement entered into with Bio Holding. Terms of this SRA are being negotiated and payments under this SRA are due within 12 months from the date the SRA is executed. As of December 31, 2009, our additional material contractual obligations are payments due under an SRA associated with our bacterial license agreement with UCD in the amount of $81,300, which was the final installment due and was paid in January 2010, and a note payable to a related party in the amount of $25,000, which is due in June 2010.

During the second half of fiscal year 2010, we expect to increase our research and development expenditures commensurate with the requirements associated with anticipated SRAs with UCD in the areas of viral infection and graft host technology. As of December 31, 2009, we expect that the total expenditure levels for these anticipated SRAs will be approximately $760,000 and will be paid over approximately the next 18 months. We expect to fund a significant portion of these expenditures from proceeds generated from the PPO.

- 28 -

Director Warrant Issuances for the Quarter Ended December 31, 2009

On October 1, 2009, the Board of Directors (the “Board”) approved a grant of 50,000 common stock purchase warrants exercisable at $3.00 per share and expiring on October 1, 2016 to a director for his second year of service on our Board of Directors (the “Board”). The warrants vest on September 30, 2010 if the director has continuously served as a director of the Company through such date. We valued these warrants at $124,854 using the Black-Scholes model with the following assumptions: exercise price of $3.00, expected life of seven years, estimated fair value of our common stock price of $3.00 at date of grant, dividend yield of 0%, interest rate of 3.02% and volatility of 100.0%.

On October 12, 2009 as consideration for consulting service agreements that we executed with one of our directors and the chairperson of our scientific advisory board, and an additional member of our scientific advisory board, the Board approved the grant to these two individuals of 50,000 and 100,000 common stock purchase warrants, respectively, exercisable at $3.00 per share and expiring October 12, 2014. The warrants vest on October 11, 2010 if the individuals have continuously provided service to the Company through such date. We valued these warrants at $338,272 using the Black-Scholes model with the following assumptions: exercise price of $3.00, expected life of five years, estimated fair value of our common stock price of $3.00 at date of grant, dividend yield of 0%, interest rate of 2.37% and volatility of 100.0%.

On October 12, 2010, our Board appointed a new director to our Board as a result of a resignation of a director. All previously recorded share-based compensation related to the unvested warrants for this director was reversed in the quarter ended December 31, 2009. Also on October 12, 2009, the Board approved the grant of 100,000 common stock purchase warrants exercisable at $3.00 per share and expiring on October 12, 2016 to the new director for his first year service as a director. The warrants vest on October 11, 2010 if the director has continuously served as a director of the Company through such date. We valued these warrants at $249,709 using the Black-Scholes model with the following assumptions: exercise price of $3.00, expected life of seven years, estimated fair value of our common stock price of $3.00 at date of grant, dividend yield of 0%, interest rate of 3.02% and volatility of 100.0%.

On December 16, 2009, our Board approved a grant to our acting chief executive officer of 600,000 common stock purchase warrants exercisable at $3.00 per share and expiring on November 13, 2016. The warrants vest and become exercisable in four equal installments on March 31, 2010, March 31, 2011, March 31, 2012 and March 31, 2013, subject to continuous service with the Company. We valued these warrants at $1,498,251 using the Black-Scholes model with the following assumptions: exercise price of $3.00, expected life of seven years, estimated fair value of our common stock price of $3.00 at date of grant, dividend yield of 0%, interest rate of 2.92% and volatility of 100.0%.

On December 16, 2009, our Board approved a grant to our chief financial officer of 300,000 common stock purchase warrants exercisable at $3.00 per share and expiring on November 13, 2016. The warrants vest and become exercisable as follows: 60,000 shares on November 20, 2009, 80,000 shares on September 30, 2010, 80,000 shares on September 30, 2011, and 80,000 shares on September 30, 2012, all subject to continuous service with the Company. We valued these warrants at $749,126 using the Black-Scholes model with the following assumptions: exercise price of $3.00, expected life of seven years, estimated fair value of our common stock price of $3.00 at date of grant, dividend yield of 0%, interest rate of 2.92% and volatility of 100.0%.

Results of Operations for the Three Months Ended December 31, 2009 Compared to the Three Months Ended December 31, 2008

For the three months ended December 31, 2009 (the “December 2009 quarter”), we reported a net loss of $903,418 as compared to a net loss of $339,959 for the three months ended December 31, 2008 (the “December 2008 quarter”), an increase of $563,459. We have not reported any revenue since inception.

- 29 -

General and administrative expenses for the December 2009 quarter were $831,519, which included $598,142 of share-based compensation, as compared to $239,952 for the December 2008 quarter, which included $122,372 of share-based compensation. Management views general and administrative expenses, exclusive of share-based compensation, as an important non-GAAP measure, as we are in development stage, have not recorded any revenue and closely monitor operating expenses to manage and control cash. Management also believes this measure is helpful to investors so they can better understand our cash expenditures. Accordingly, excluding share-based compensation, general and administrative expenses in the December 2009 quarter increased $115,797 or approximately 98% from the December 2008 quarter. This increase was primarily due to public company reporting and administrative related expenses in the areas of external audit and reporting, legal, stock administration, investor relations and insurance that were incurred in the December 2009 quarter and not incurred in the December 2008 quarter when we were not an SEC reporting company. Also for the December 2009 quarter, we had increases in consulting and scientific advisory expenses as compared to December 2008 quarter.

Research and development expenses for the December 2009 quarter were $-0- as compared to $81,300 for the December 2008 quarter as a result of the SRA expense incurred in the December 2008 quarter related to our bacterial license. We did not enter into any additional SRAs during the December 2009 quarter.

In the December 2009 quarter, we recorded a charge in the amount of $528,000 related to a modification of 250,000 warrants that were exercised during the December 2009 quarter. The estimated fair value of the modification was calculated using the Black-Scholes model.

Interest income, net of interest expense, for the December 2009 quarter was $1,063 and was primarily comprised of interest income of $1,438 from cash invested in an interest bearing, money market account.

Results of Operations for the Nine Months Ended December 31, 2009 Compared to the Nine Months Ended December 31, 2008

For the nine months ended December 31, 2009, we reported a net loss of $3,504,144 as compared to a net loss of $1,046,902 for the nine months ended December 31, 2008, an increase of $2,457,242.

General and administrative expenses for the nine months ended December 31, 2009 were $1,931,874, which included $1,314,164 of share-based compensation, as compared to $761,540 for the nine months ended December 31, 2008, which included $428,184 of share-based compensation. Management views general and administrative expenses, exclusive of share-based compensation, as an important non-GAAP measure, as we are in development stage, have not recorded any revenue and closely monitor operating expenses to manage and control cash. Management also believes this measure is helpful to investors so they can better understand our cash expenditures. Accordingly, excluding share-based compensation, general and administrative expenses for the nine months ended December 31, 2009 increased $284,354 or approximately 85% from the nine months ended December31, 2008. This increase was primarily due to public company reporting and administrative related expenses in the areas of external audit and reporting, legal, stock administration, investor relations and related travel and insurance that were incurred for the nine months ended December 31, 2009 and not incurred for the nine months ended December 31, 2008 when we were not an SEC reporting company. Also for the nine months ended December 31, 2009, we had increases in consulting and scientific advisory expenses as compared to the nine months ended December 31, 2008.

During the September 2009 quarter, we executed a license agreement with a related party. The total value ascribed to the license agreement was $1,495,000, and this amount was expensed as a license fee during the September 2009 quarter.

Research and development expenses for the nine months ended December 31, 2009 were $-0- as compared to $241,300 for the nine months ended December 31, 2008 as a result of the SRA expense incurred for the nine months ended December 31, 2008 related to our bacterial license.

Interest income, net of interest expense, for the nine months ended December 31, 2009 was $1,692 and was primarily comprised of interest income of $3,317 from cash invested in an interest bearing, money market account.

- 30 -

Critical Accounting Policies

We prepare our financial statements in accordance with US GAAP. The accounting policies most fundamental to the understanding of our financial statements are those relating to our use of estimates, to the accounting for license agreements and the impairment analysis of the capitalized license costs, the valuation, classification and recording of debt and equity transactions, including those that include common stock purchase warrants, and assumptions used under share-based compensation arrangements.

Our significant accounting policies and estimates are disclosed in the notes to our consolidated financial statements contained in our Annual Report on Form 10-K for the fiscal year ended March 31, 2009.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide the information under this item.

Item 4T. Controls and Procedures.

Disclosure Controls and Procedures

We are responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Acting Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Acting Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of December 31, 2009. Based on this evaluation, our Acting Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of this date.

Internal Control over Financial Reporting

There was no change in our internal control over financial reporting during the quarter ended December 31, 2009 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

- 31 -

PART II - OTHER INFORMATION.

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

None.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Warrant Grants

On October 1, 2009, the Board approved a grant of 50,000 warrants to purchase our common stock to Michael Wort, one of our directors, as compensation for his services as a director. The warrants vest and become exercisable on September 30, 2010 with an exercise price of $3.00 per share. The warrants expire on October 1, 2016. The warrants were issued under the Company’s director compensation plan and under Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”).

On October 12, 2009, the Board approved a grant of 50,000 warrants to purchase our common stock to Michael Iseman, one of our directors and the chairperson of our scientific advisory board, as compensation for his additional services as a consultant on certain scientific matters. The warrants vest and become exercisable on October 11, 2010 with an exercise price of $3.00 per share. The warrants expire on October 12, 2014. The warrants were issued under Section 4(2) of the Securities Act.

On October 12, 2009, the Board approved a grant of 100,000 warrants to purchase our common stock to Eli Lewis, a member of our scientific advisory board, as compensation for his additional services as a consultant on certain scientific matters. The warrants vest and become exercisable on October 11, 2010 with an exercise price of $3.00 per share. The warrants expire on October 12, 2014. The warrants were issued under Section 4(2) of the Securities Act.

On October 12, 2009, the Board approved a grant of 50,000 warrants to purchase our common stock to Jeffrey Sperber, one of our directors, as compensation for his services as a director. The warrants vest and become exercisable on October 11, 2009 with an exercise price of $3.00 per share. The warrants expire on October 12, 2016. The warrants were issued under the Company’s director compensation plan and under Section 4(2) of the Securities Act.

On December 16, 2009, our Board approved a grant to Charles Dinarello, our acting chief executive officer and a director, of 600,000 common stock purchase warrants exercisable at $3.00 per share and expiring on November 13, 2016. The warrants vest and become exercisable in four equal installments on March 31, 2010, March 31, 2011, March 31, 2012 and March 31, 2013, subject to continuous service with the Company. The warrants were issued under Section 4(2) of the Securities Act.

On December 16, 2009, our Board approved a grant to Robert Ogden, our chief financial officer, of 300,000 common stock purchase warrants exercisable at $3.00 per share and expiring on November 13, 2016. The warrants vest and become exercisable as follows: 60,000 shares on November 20, 2009, 80,000 shares on September 30, 2010, 80,000 shares on September 30, 2011, and 80,000 shares on September 30, 2012, all subject to continuous service with the Company.

- 32 -

Warrant Exercises under Cashless Exercise Provisions

During the December 2009 quarter, certain investors exercised common stock purchase warrants under cashless exercise provisions. The following table represents the net shares surrendered in these cashless warrant exercises.

ISSUER PURCHASES OF EQUITY SECURITIES

Period	(a) Total Number of Shares (or Units) Purchased	(b) Average Price Paid per Share (or Unit)	(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs)

October 1 to October 31, 2009	4,952	$15.00	-	-

November 1 to November 30, 2009	-	-	-	-

December 1 to December 31, 2009	20,834	$12.00	-	-

TOTAL	25,786	$12.58	-	-

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security Holders.

None.

Item 5. Other Information.

As previously reported in our Current Report on Form 8-K filed on January 5, 2010 and as discussed in Item 2 of this report, in December 2009, we entered into subscription agreements with certain investors relating to the issuance and sale of PPO Units in the PPO. On January 22, 2010 and January 29, 2010, we entered into additional subscription agreements with investors for the issuance and sale of 638,260 PPO Units for an aggregate subscription price of $1,595,650. On January 29, 2010, we closed the PPO. We sold an aggregate of 794,260 PPO Units in the PPO, which generated net proceeds of $1,786,260 after deducting offering expenses of $199,000. A copy of the Form of Subscription Agreement and Letter of Investment Intent and Form of Warrant are filed as Exhibits 10.2 and 10.3, respectively, to this report and are incorporated herein by reference.

In connection with the PPO, we were obligated to sell to the placement agent for a nominal fee warrants to purchase 10% of the total number of PPO Units sold in the PPO. Upon closing of the PPO, we became obligated to issue 158,852 PPO PA Warrants to the placement agent. Half of the PPO PA Warrants are exercisable at $2.50 per share and half of the PPO PA Warrants are exercisable at $3.75 per share. The PPO PA warrants expire on January 29, 2015 and are exercisable beginning on July 28, 2010.

The PPO Units and the PPO PA Warrants were issued exempt from registration pursuant to Regulation D of the Securities Act and constitute “restricted securities” under Rule 144 of the Securities Act.

- 33 -

Item 6. Exhibits.

EXHIBIT #

DESCRIPTION

3.1	Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form SB-2 filed on March 2, 2007)

3.2	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K filed on January 5, 2010)

3.3	Articles of Amendment for Across America Financial Services, Inc. including Amendment to Articles of Incorporation of Across America Financial Services, Inc. (incorporated by reference to Exhibit 3.3 to the Registrant’s Form 8-K filed on June 2, 2009)

10.1	License Agreement by and between Bio Holding, Inc. and Omni Bio Pharmaceutical, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 8-K filed on October 2, 2009)

10.2	Form of Subscription Agreement and Letter of Investment Intent #

10.3	Form of Warrant #

31.1	Certification of Acting Chief Executive Officer Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 #

31.2	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 #

32.1	Certification of Acting Chief Executive Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code #

32.2	Certification of Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code #

# Filed herewith

- 34 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	OMNI BIO PHARMACEUTICAL, INC.


February 4, 2010	By: /s/ Charles A. Dinarello
	Charles A. Dinarello
	Acting Chief Executive Officer
	(Principal Executive Officer)


February 4, 2010	By: /s/ Robert C. Ogden
	Robert C. Ogden
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

- 35 -

Attached files

OMNI BIO PHARMACEUTICAL, INC. Reports

Also read